Israeli telehealth startup Tyto Care announced this month that its devices for remote medical examinations would become available across the US at over 300 Best Buy stores nationwide.
Tyto Care specializes in telehealth, connecting people to clinicians to provide virtual home examination and diagnosis solutions. The company’s offerings include TytoHome for patients, TytoPro for professionals, and TytoClinic for remote point-of-care testing. It also has a complete telehealth platform, analytics, built-in guidance technology, and machine learning algorithms.
Sign up for our free weekly newsletterSubscribe
Tyto Care’s TytoHome was initially rolled out at Best Buy locations in the Midwest. It’s also available for sale to Best Buy online consumers.
The handheld examination device comes with attachments that can examine the heart, lungs, skin, ears, throat and abdomen, as well as measure body temperature, to enable remote diagnosis of acute care situations like ear infections, sore throats, fever, cold and flu, allergies, and so on. It enables users to perform comprehensive medical exams and send information to a primary care provider.
TytoHome sells for $299.99 and a “visit” with a provider “costs $59.99 or less depending on the nature of the visit and/or the user’s health insurance plan,” the company said in a statement.
“Launching TytoHome nationally is a huge milestone for us and we are proud to be working alongside Best Buy in fulfilling their commitment to expanding digital health options for consumers,” said Dedi Gilad, CEO and co-founder of Tyto Care.
“Tyto Care’s mission has always been to make high-quality health care accessible and on demand, from any location, to as many people as possible. This launch signifies a major step forward for the future of health care,” he added.
Gilad co-founded Tyto Care alongside Ofer Tzadik in 2012, after spending many days and nights in emergency care as a parent of young children.
Tyto Care has FDA clearance and launched its products in the US in 2017. It also has a CE mark for Europe and gained Health Canada approval in 2018.